A recent study meta-analysed the existing work where molecular imaging brain scans of humans had been carried out.
Hence, by combining photoacoustic imaging with molecular imaging (i.e., photoacoustic molecular imaging), brain glioma can be diagnosed with high sensitivity, specificity, and resolution at greater depth [18, 19, 20].
Molecular imaging of brain tryptophan metabolism and serotonergic function is a relatively new approach to study cerebral substrates of mood disorders and depression.
The tunable optical properties of these agents have primarily been used in preclinical optical imaging for a variety of cancer applications, including cellular and molecular imaging of brain tumors, including gliomas [ 72– 72].
Standard laboratory testing, such as blood tests, combined with the newly developed and state-of-the-art brain molecular imaging techniques used to detect brain pathological biomarkers will facilitate investigation of this possibility.
These changes may indicate an imbalance between the serotonin and kynurenine pathways and serve as a molecular imaging marker of brain tumor-associated depression.
This could possibly be done if a greater emphasis is placed on the molecular interaction between different transport systems in the BBB, the toxicity induced by drug delivery technologies and molecular imaging of the brain and vasculature (Neuwelt et al., 2008).
Detection of microglial distribution and activation by molecular imaging of the brain using positron emission tomography has underscored the relevance of microglial activation as a relevant biomarker of disease in multiple neurological and psychiatric conditions (Jacobs and Tavitian, 2012; Politis et al., 2012; Venneti et al., 2013).
The results of the study suggest that anti-IGFBP7 sdAbs and anti-IGFBP7 sdAb-PEGylated-NPs are both promising molecular imaging agents for targeting brain tumour vessels with potential for clinical translation.
Topics covered in this special issue include advances in molecular imaging modalities in oncological disease management, image-guided approach of brain function, stem cell technology, and receptor based imaging approach.
Methods based on molecular imaging have recently made it possible to assess brain Aβ deposition in patients with AD.
